Josep Carreras Leukaemia Research Institute

What Josep Carreras Leukaemia Research Institute does

The Josep Carreras Leukaemia Research Institute (IJC), legally constituted as Fundaci\u00f3 Institut de Recerca contra la Leuc\u00e8mia Josep Carreras, is a non-profit biomedical research foundation headquartered in Badalona, Barcelona, and registered in the Register of Foundations of the Generalitat of Catalonia (number 2674, CIF G65454308). Founded in 2010 and active across six distributed locations in the Barcelona and Girona area (Can Ruti, Sant Pau, Cl\u00ednic, Mar, Josep Trueta, and Sant Joan de D\u00e9u), the institute employs 398 professionals organized into 39 research groups across 4 programs, dedicated to studying and eradicating leukemia, lymphoma, multiple myeloma, and other hematological malignancies across the lifespan, including pediatric cancers. Its core technology stack is a multi-omics research platform combining genomics, epigenomics, transcriptomics (including spatial transcriptomics, with practical guides built on over 1,000 samples), proteomics, cytogenetics, single-cell analysis, advanced microscopy, and cytometry, supported by artificial intelligence and reinforced by the proprietary Path2CURE translational research program.

IJC's business model is that of a publicly funded research foundation rather than a commercial enterprise: it generates no product revenue and does not sell commercial services. Operating capacity is financed through a portfolio of competitive research grants, foundation and philanthropic contributions (notably Deutsche Jos\u00e9 Carreras Leuk\u00e4mie-Stiftung), Spanish public funding (including the prestigious Severo Ochoa Center of Excellence accreditation, AECC acreditaci\u00f3n, and HR Excellence in Research recognition), and donations. Recent milestones include a five-year, $6.5 million international follicular lymphoma consortium launched in December 2025, the EHA Clinical Excellence Award granted to Dr Josep Maria Ribera in June 2026, and publication output in NEJM, Nature, Cell Reports Medicine, Nature Communications, and Trends in Biotechnology. The institute's primary beneficiaries are patients with hematological malignancies, with its academic and clinical collaborators (eight leading Catalan hospitals and the Universities of Barcelona and Aut\u00f2noma de Barcelona) and an expanding base of international consortium partners (notably in the United States) serving as its principal operational counterparts.

Name

Josep Carreras Leukaemia Research Institute

Legal name

Fundació Institut de Recerca contra la Leucèmia Josep Carreras

Website

https://carrerasresearch.org

Company type

Private

Founded year

2010

Operating status

Operating

Headcount range

101–250 employees

Short description

The Josep Carreras Leukaemia Research Institute (IJC) is a non-profit foundation operating six locations in Catalonia that conducts multi-omics and AI-driven basic, translational, and clinical research on leukemia, lymphoma, and other blood cancers across the lifespan, funded by competitive grants, public programs, and philanthropy.

Ownership category

akta.pro rank

Product category

Biomedical Research

NAICS

Medical and Diagnostic Laboratories (6215), Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Services-Medical Laboratories (8071)

akta.pro primary industry

Genomics & Molecular Diagnostics (Trial Support) (HLAGAEAD)

akta.pro secondary industries

Bioanalytical & PK/PD Sample Analysis (Trial Support) (HLAGAEAG), Transcriptomics & Gene Expression Profiling Services (HLAGANAE)

Keywords

• Leukemia research
• Hematological malignancy research
• Translational biomedical research
• Multi-omics genomics
• Cancer diagnostics research

Headquarters

HQ city

Badalona

HQ country

Spain

HQ region

Europe

Offices6 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Others

Revenue model

1. Competitive Research Grants (International): Multi-year competitive grant funding for collaborative research projects. Example: $6.5 million five-year international consortium grant for follicular lymphoma research.
2. Foundation Grants & Public Funding: Funding from foundations such as the Deutsche José Carreras Leukämie-Stiftung and from government/public sources (including Severo Ochoa accreditation and recognition from Asociación Española Contra el Cáncer). Registered as Fundació Institut de Recerca contra la Leucèmia Josep Carreras (CIF G65454308) in the Register of Foundations of the Generalitat of Catalonia (number 2674).
3. Donations & Philanthropy: Operated as a non-profit foundation, accepting donations and philanthropic contributions (e.g., Innomed Awards, public donation channels) to support biomedical research projects with healthcare transfer potential.
4. Consortium & Institutional Funding: International consortium funding for collaborative research with multiple academic and clinical centers, such as the follicular lymphoma consortium.

Go-to-market motion3 records

Marketing channels9 records

Core offering

The Josep Carreras Leukaemia Research Institute (IJC) is a non-profit research foundation that conducts basic, translational, and clinical research on leukemia, lymphoma, multiple myeloma, and other hematological malignancies. It operates 4 overarching research programs across 39 research groups, supports them with 9 shared core facilities (genomics, proteomics, cytometry, cytogenetics, advanced microscopy, single cell, microarrays, sample circuit, and Path2CURE translational), and channels discoveries into clinical application through the Path2CURE program and international consortia across six hospital-university locations in Catalonia.

Product overview

The Josep Carreras Leukaemia Research Institute (IJC) operates as a single integrated research organization rather than a multi-product SaaS platform, delivering its mission across four interlocking pillars: (1) Research Programs — 4 programs organized into 39 research groups covering leukemia, lymphoma, myeloma, epigenetics, chromatin biology, immunotherapy, stem cell biology, and endothelial biology; (2) Core Facilities — a shared infrastructure including Genomics, Proteomics, Cytometry, Cytogenetics, Advanced Microscopy, Single Cell, Microarrays, Sample Circuit, and Translational (Path2Cure) — which feed (3) the Path2Cure translational program that moves discoveries into clinical application; and (4) the Multi-site Research Locations network (IJC Can Ruti, Sant Pau, Clínic, Mar, Josep Trueta, and Sant Joan de Déu) distributed across Barcelona and Girona. Layered on top of these pillars are collaborative offerings such as the International Follicular Lymphoma Consortium (a five-year, $6.5M alliance launched in late 2025) and public-facing channels including the Scientific Publications and Latest News portal and the Events and Symposia program (CLEPIC, Immunity in Haematological Malignancies, MRD lectures). The institute employs artificial intelligence and multi-omics analytics across these offerings for research and translational work.

Differentiator

Problem solved

Functional benefit

Brands

• Path2Cure: Translational research initiative referenced as a distinct program area on the institute's website.

Products and services

• Path2CURE Translational Research Program Translational research program (also operated as a core facility) that moves laboratory discoveries into clinical applications for patients with leukemia, lymphoma, and other hematological malignancies. Used by IJC's 39 research groups and clinical collaborators.
• IJC Core Facilities (Genomics, Proteomics, Cytometry, Cytogenetics, Advanced Microscopy, Single Cell, Microarrays, Sample Circuit) A suite of nine shared core research facilities (Genomics, Proteomics, Cytometry, Cytogenetics, Advanced Microscopy, Single Cell, Microarrays, Sample Circuit, and Translational/Path2CURE) providing high-throughput molecular and cellular analysis services to the institute's researchers and external collaborators.
• International Follicular Lymphoma Consortium Five-year, $6.5 million international research consortium launched in December 2025 to develop new diagnostics and treatments for follicular lymphoma (a non-Hodgkin lymphoma subtype), coordinated by IJC with research partners in Spain and the United States, leveraging artificial intelligence and genomics.

Quantifiable outcome

• $6.5M five-year international consortium on follicular lymphoma
• +2 more outcomes

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature6 records

Scale indicators11 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Institut Pasteur: Major French non-profit biomedical research foundation with global brand recognition, similar foundation-based governance and public health research mission. Comparable as a European research foundation of similar institutional pedigree.
• Dana-Farber Cancer Institute: A leading US-based cancer research and treatment center with deep specialization in hematological malignancies, including leukemia and lymphoma. Comparable as a globally recognized hematology-focused cancer research institution, but at substantially larger scale.
• Wellcome Sanger Institute: UK-based genomics and biomedical research institute. Comparable as a large-scale genomics and multi-omics research institution with high publication output, though broader in scope than hematology.
• Memorial Sloan Kettering Cancer Center: A major US cancer research and treatment institution with extensive hematology programs. Comparable as a large, established cancer research center publishing in top-tier journals and running translational research programs.
• Fred Hutchinson Cancer Center: Major US cancer research center with strong programs in leukemia and lymphoma, and a translational model similar to IJC's Path2CURE approach. Comparable as a research-intensive cancer center with a translational pipeline and grant-funded model.

Direct peers

• IDIBAPS - Institut d'Investigacions Biomèdiques August Pi i Sunyer: Barcelona-based biomedical research institute affiliated with Hospital Clínic, overlapping with one of IJC's own research locations. Comparable as a translational research hub co-located with a major Catalan hospital.
• Centro Nacional de Investigaciones Oncológicas (CNIO): Spain's national cancer research centre, also publicly funded and located in Madrid. Most directly comparable as a national, government-recognized cancer research institute competing for similar Spanish and European grants and talent in oncology research.
• Centro de Regulación Genómica (CRG): Barcelona-based genomics and systems biology research institute, also a CERCA member with Severo Ochoa accreditation. Comparable as a peer institute combining genomics, multi-omics, and biomedical research in Catalonia.
• Institut de Recerca Biomèdica (IRB Barcelona): Barcelona-based biomedical research institute also recognized by the Catalan CERCA network and focused on fundamental and translational biomedical research. Comparable as a peer research institute in the same Catalan biomedical ecosystem.

Others

• European Hematology Association (EHA): Not a research institute but the professional association through which IJC leaders (e.g., Dr. Ribera's EHA Clinical Excellence Award) are recognized. Relevant as the ecosystem of hematology research in which IJC operates.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/CarrerasIJC

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Josep Carreras Leukaemia Research Institute